{
    "info": {
        "nct_id": "NCT03441061",
        "official_title": "Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease",
        "inclusion_criteria": "* Patients with B-lineage ALL in hematologic complete remission (CR) with molecular failure (ie, had never achieved an MRD-negativity status before inotuzumab ozogamicin) or had a molecular relapse (ie, became MRD positive after having been MRD negative) starting at any time point after 3 months of frontline therapy. Molecular disease or minimal residual disease is defined by any level of measurable residual disease identified by multicolor flow cytometry, PCR and/or next-generation sequencing (NGS).\n* Patients with B-lineage ALL in at least marrow CR in salvage 1 and beyond with MRD failure at any time point after 1 month of salvage therapy are allowed, including patients who received prior allogeneic stem cell transplantation.\n* Patients with Ph+ ALL can be enrolled in CR1 or CR2 and beyond. A TKI will be added at the discretion of the treating physician. MRD for these patients will be defined by either 1.) a ratio of BCR-ABL1 to ABL1 by PCR of ≥ 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of ≥ 0.01% for patients with non-p210 transcripts, or 2.) detectable MRD at any level of measurable residual disease identified by multicolor flow cytometry and/or by NGS.\n* Performance status of 0, 1, or 2\n* Creatinine clearance >= 15 ml/min\n* Bilirubin < 1.5 X upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 X ULN\n* No active or co-existing malignancy with life expectancy less than 12 months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Pregnant or nursing women\n* Known to be human immunodeficiency virus positive (HIV+)\n* Active and uncontrolled disease/infection as judged by the treating physician\n* Unable or unwilling to sign the consent form\n* Active central nervous system (CNS) or extramedullary disease\n* Monoclonal antibodies therapy within 2 weeks before study entry\n* Radiotherapy or cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) or any investigational drug within 2 weeks before study entry",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* No active or co-existing malignancy with life expectancy less than 12 months",
            "criterions": [
                {
                    "exact_snippets": "No active or co-existing malignancy",
                    "criterion": "active or co-existing malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "life expectancy less than 12 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with B-lineage ALL in at least marrow CR in salvage 1 and beyond with MRD failure at any time point after 1 month of salvage therapy are allowed, including patients who received prior allogeneic stem cell transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Patients with B-lineage ALL",
                    "criterion": "B-lineage acute lymphoblastic leukemia (ALL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least marrow CR in salvage 1 and beyond",
                    "criterion": "marrow complete remission (CR) in salvage 1 and beyond",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "at least complete remission (CR)"
                        },
                        {
                            "requirement_type": "salvage number",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "MRD failure at any time point after 1 month of salvage therapy",
                    "criterion": "minimal residual disease (MRD) failure after salvage therapy",
                    "requirements": [
                        {
                            "requirement_type": "MRD failure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time after salvage therapy",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including patients who received prior allogeneic stem cell transplantation",
                    "criterion": "prior allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history of allogeneic stem cell transplantation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin < 1.5 X upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin < 1.5 X upper limit of normal (ULN)",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with B-lineage ALL in hematologic complete remission (CR) with molecular failure (ie, had never achieved an MRD-negativity status before inotuzumab ozogamicin) or had a molecular relapse (ie, became MRD positive after having been MRD negative) starting at any time point after 3 months of frontline therapy. Molecular disease or minimal residual disease is defined by any level of measurable residual disease identified by multicolor flow cytometry, PCR and/or next-generation sequencing (NGS).",
            "criterions": [
                {
                    "exact_snippets": "Patients with B-lineage ALL",
                    "criterion": "B-lineage acute lymphoblastic leukemia (ALL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in hematologic complete remission (CR)",
                    "criterion": "hematologic complete remission (CR)",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "complete remission"
                        }
                    ]
                },
                {
                    "exact_snippets": "with molecular failure (ie, had never achieved an MRD-negativity status before inotuzumab ozogamicin)",
                    "criterion": "molecular failure (MRD-negativity status before inotuzumab ozogamicin)",
                    "requirements": [
                        {
                            "requirement_type": "MRD-negativity status before inotuzumab ozogamicin",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "or had a molecular relapse (ie, became MRD positive after having been MRD negative)",
                    "criterion": "molecular relapse (MRD positive after MRD negative)",
                    "requirements": [
                        {
                            "requirement_type": "MRD status change",
                            "expected_value": "became MRD positive after being MRD negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "starting at any time point after 3 months of frontline therapy",
                    "criterion": "time since start of frontline therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since start of frontline therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Molecular disease or minimal residual disease is defined by any level of measurable residual disease identified by multicolor flow cytometry, PCR and/or next-generation sequencing (NGS)",
                    "criterion": "measurable residual disease (MRD) detection method",
                    "requirements": [
                        {
                            "requirement_type": "detection method",
                            "expected_value": [
                                "multicolor flow cytometry",
                                "PCR",
                                "next-generation sequencing (NGS)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance >= 15 ml/min",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance >= 15 ml/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "ml/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with Ph+ ALL can be enrolled in CR1 or CR2 and beyond. A TKI will be added at the discretion of the treating physician. MRD for these patients will be defined by either 1.) a ratio of BCR-ABL1 to ABL1 by PCR of ≥ 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of ≥ 0.01% for patients with non-p210 transcripts, or 2.) detectable MRD at any level of measurable residual disease identified by multicolor flow cytometry and/or by NGS.",
            "criterions": [
                {
                    "exact_snippets": "Patients with Ph+ ALL",
                    "criterion": "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "can be enrolled in CR1 or CR2 and beyond",
                    "criterion": "remission status",
                    "requirements": [
                        {
                            "requirement_type": "remission phase",
                            "expected_value": [
                                "CR1",
                                "CR2 or beyond"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "A TKI will be added at the discretion of the treating physician",
                    "criterion": "TKI administration",
                    "requirements": [
                        {
                            "requirement_type": "discretion of treating physician",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "MRD for these patients will be defined by either 1.) a ratio of BCR-ABL1 to ABL1 by PCR of ≥ 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of ≥ 0.01% for patients with non-p210 transcripts",
                    "criterion": "BCR-ABL1 to ABL1 ratio by PCR",
                    "requirements": [
                        {
                            "requirement_type": "ratio",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.01,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "detectable MRD at any level of measurable residual disease identified by multicolor flow cytometry and/or by NGS",
                    "criterion": "measurable residual disease (MRD) by multicolor flow cytometry and/or NGS",
                    "requirements": [
                        {
                            "requirement_type": "detectable",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 X ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... < 3 X ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) < 3 X ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "X ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Performance status of 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Performance status of 0, 1, or 2",
                    "criterion": "performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Active and uncontrolled disease/infection as judged by the treating physician",
            "criterions": [
                {
                    "exact_snippets": "Active and uncontrolled disease/infection",
                    "criterion": "disease/infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "as judged by the treating physician",
                    "criterion": "treating physician judgment",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Monoclonal antibodies therapy within 2 weeks before study entry",
            "criterions": [
                {
                    "exact_snippets": "Monoclonal antibodies therapy within 2 weeks before study entry",
                    "criterion": "monoclonal antibodies therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks before study entry"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or nursing women",
            "criterions": [
                {
                    "exact_snippets": "Pregnant or nursing women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnant or nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known to be human immunodeficiency virus positive (HIV+)",
            "criterions": [
                {
                    "exact_snippets": "Known to be human immunodeficiency virus positive (HIV+)",
                    "criterion": "human immunodeficiency virus (HIV) status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiotherapy or cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) or any investigational drug within 2 weeks before study entry",
            "criterions": [
                {
                    "exact_snippets": "Radiotherapy ... within 2 weeks before study entry",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) ... within 2 weeks before study entry",
                    "criterion": "cancer chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "intrathecal prophylaxis",
                                "low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "any investigational drug within 2 weeks before study entry",
                    "criterion": "investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active central nervous system (CNS) or extramedullary disease",
            "criterions": [
                {
                    "exact_snippets": "Active central nervous system (CNS) ... disease",
                    "criterion": "central nervous system (CNS) disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active ... extramedullary disease",
                    "criterion": "extramedullary disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable or unwilling to sign the consent form",
            "criterions": [
                {
                    "exact_snippets": "Unable or unwilling to sign the consent form",
                    "criterion": "ability and willingness to sign consent form",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}